Trump Administration Imposes 100% Tariffs on Imported Patented Pharmaceuticals to Bolster Domestic Supply Chain

President Donald J. Trump signed an executive order on April 2, 2026, imposing unprecedented 100% tariffs on imported patented pharmaceuticals and their active pharmaceutical ingredients (APIs), citing grave national security concerns. The proclamation, issued under Section 232 of the Trade Expansion Act of 1962, marks a dramatic escalation in U.S. efforts to reduce reliance on foreign drug manufacturing—a vulnerability exposed by the COVID-19 pandemic and geopolitical instability. The move comes after a Department of Commerce investigation found that 53% of patented drugs and just 15% of patented APIs consumed in the U.S. are now produced domestically, leaving the nation dangerously exposed to supply chain disruptions.

Why the U.S. Is Targeting Pharmaceutical Imports Under Section 232

Section 232 of the Trade Expansion Act grants the president authority to impose tariffs or other trade restrictions on imports deemed harmful to national security. Unlike traditional trade disputes focused on economic harm, Section 232 targets threats to the nation’s ability to function during crises—military conflicts, pandemics, or industrial sabotage. The Department of Commerce’s investigation, led by Commerce Secretary Wilbur Ross, concluded that America’s heavy reliance on imported pharmaceuticals—particularly APIs, which are the building blocks of all drugs—creates a ‘fragile supply chain’ vulnerable to disruption. According to the FDA, 85% of all APIs used in U.S.-consumed drugs are manufactured overseas, with China and India dominating production. The report warned that dependence on foreign suppliers could ‘limit access to life-saving medications’ during a global emergency, citing examples like the 2020 hydroxychloroquine shortage and ongoing insulin price volatility.

The National Security Case: From Military Readiness to Pandemic Preparedness

The proclamation frames pharmaceuticals not just as economic goods but as ‘critical components of national defense and public health security.’ The U.S. military, for instance, relies on patented drugs to treat service members with cancer, autoimmune disorders, and infectious diseases. During the Iraq and Afghanistan wars, supply chain bottlenecks for painkillers like fentanyl derivatives and antibiotics led to temporary shortages, underscoring the risk of over-reliance on foreign production. The COVID-19 pandemic further exposed vulnerabilities: shortages of sedatives, ventilator components, and even basic pain relievers forced the U.S. to compete with global buyers for limited supplies. The Secretary’s report also highlights China’s dominance in API production, noting that ‘foreign government intervention’—such as subsidies, export controls, or industrial policies—has distorted global markets and undermined U.S. competitiveness.

The Role of Active Pharmaceutical Ingredients (APIs) in the Supply Chain

APIs are the chemical compounds that give drugs their therapeutic effect. For example, the API in Pfizer’s COVID-19 antiviral Paxlovid is nirmatrelvir, while insulin’s API is recombinant human insulin. The U.S. once produced 90% of its own APIs, but by 2025, that figure had plummeted to just 15% as manufacturers relocated to countries with lower labor and regulatory costs. The shift has left the U.S. vulnerable to ‘supply chain fragility,’ as seen when India—home to 10% of global API production—imposed export restrictions during the pandemic. The Trump administration’s tariffs aim to reverse this trend by incentivizing companies to ‘onshore’ API production through a phased tariff reduction program: companies with approved onshoring plans will pay a 20% tariff initially, rising to 100% in 2030 unless they meet domestic production milestones.

How the Tariffs Work: Exemptions, Phased Rates, and Enforcement

The proclamation imposes a baseline 100% ad valorem tariff on all imported patented pharmaceuticals and APIs listed in Annex I, effective July 31, 2026, for companies named in Annex III, and September 29, 2026, for all others. However, the administration carved out several exemptions and tiered rates to balance economic impact with national security goals. For example, companies with approved onshoring plans—such as those committing to build U.S.-based API manufacturing facilities—will initially pay just 20%, with the rate escalating to 100% in 2030 if they fail to meet production targets. The U.S. also negotiated preferential rates with key allies: EU, Japan, South Korea, and Switzerland/Liechtenstein will face a 15% tariff, while the UK’s rate starts at 10% and phases to zero under a pending trade deal.

Exemptions for Critical Drugs and Specialty Treatments

The proclamation exempts several categories of drugs from the 100% tariff, recognizing their unique importance to public health and national security. Orphan drugs—medications for rare diseases—are fully exempt, as are nuclear medicines, plasma-derived therapies, fertility treatments, and cell and gene therapies. Medical countermeasures for chemical, biological, radiological, and nuclear threats (e.g., antidotes for nerve gas or radiation exposure) are also excluded, as are antibody drug conjugates and veterinary pharmaceuticals, provided they meet specific trade or health criteria. The Secretary of Commerce, in consultation with the USTR and HHS, will publish a Federal Register notice when such exemptions are applied, ensuring transparency.

Most-Favored-Nation (MFN) Pricing Agreements and Tariff Waivers

Companies that enter into Most-Favored-Nation (MFN) pricing agreements with the Department of Health and Human Services will receive a temporary waiver from the 100% tariff until January 20, 2029. These agreements aim to ensure that U.S. consumers have access to patented drugs at prices comparable to those paid in other high-income countries, reducing the financial burden of domestic production. The waiver applies retroactively to companies listed in Annex II of the proclamation and can be extended if companies demonstrate progress toward onshoring. The goal is to create a ‘win-win’ scenario: U.S. patients pay fair prices while pharmaceutical companies invest in domestic manufacturing.

The Economic and Political Implications of the Tariffs

The administration’s move is expected to reshape the $500 billion U.S. pharmaceutical market, which currently imports nearly $200 billion in drugs and APIs annually. While proponents argue the tariffs will revitalize domestic production, critics warn of higher drug prices and retaliatory measures from trading partners. The Pharmaceutical Research and Manufacturers of America (PhRMA), an industry trade group, has already signaled opposition, stating that tariffs could ‘disrupt global supply chains’ and ‘increase costs for American patients.’ The Congressional Budget Office estimates that the tariffs could add $10–15 billion annually to U.S. healthcare spending if passed through to consumers. Meanwhile, trade partners like the EU and China have hinted at WTO challenges, arguing that the tariffs violate international trade rules.

The Path Forward: Negotiations, Monitoring, and Future Adjustments

The proclamation directs the Secretaries of Commerce and Health and Human Services to pursue negotiations with pharmaceutical companies and foreign governments to address the ‘threatened impairment of national security.’ Within 90 days, the administration must provide an update on progress, including any agreements reached under Section 232(c)(3)(A)(i). The Commerce Secretary will also monitor imports quarterly and report any ‘circumstances indicating the need for further action’—such as a surge in imports from non-exempt countries or failure by companies to meet onshoring commitments. If a company is found to have misled the U.S. government about its onshoring plans, the Secretary can retroactively reimpose tariffs or impose additional penalties.

Key Takeaways: What You Need to Know About the New Pharmaceutical Tariffs

• President Trump signed an executive order imposing 100% tariffs on imported patented pharmaceuticals and APIs, citing national security risks. The move aims to reduce U.S. reliance on foreign production, which currently supplies 85% of APIs and 47% of patented drugs.
• Companies with approved onshoring plans will face a 20% tariff initially, rising to 100% in 2030 if they fail to meet domestic production milestones. The USTR will negotiate preferential rates with allies like the EU (15%), UK (phasing to 0%), and Japan/South Korea/Switzerland (15%).
• Exemptions apply to orphan drugs, nuclear medicines, cell/gene therapies, and medical countermeasures, as well as drugs covered by Most-Favored-Nation pricing agreements with HHS, which receive a temporary tariff waiver until 2029.
• Generic drugs and their APIs are not subject to the tariffs at this time, but the Commerce Secretary will review their status within a year and recommend further action if needed.
• The tariffs take effect on July 31, 2026 (for named companies) and September 29, 2026 (for all others), with enforcement managed by U.S. Customs and Border Protection.

Reactions from Industry, Congress, and Global Partners

The pharmaceutical industry has responded with a mix of concern and cautious optimism. While PhRMA and the Biotechnology Innovation Organization (BIO) have expressed reservations about the ‘potential for higher costs and supply disruptions,’ some generic drug manufacturers—particularly those already producing domestically—have welcomed the move. ‘This is a long-overdue step to secure our supply chains,’ said a spokesperson for Teva Pharmaceuticals, one of the largest U.S.-based generic drugmakers. ‘The pandemic showed us that we cannot afford to be dependent on foreign manufacturers for life-saving medicines.’

Congress has been divided. Senator Elizabeth Warren (D-MA) praised the tariffs as ‘a critical step to protect American patients and workers,’ while Senator Mike Crapo (R-ID) warned that ‘tariffs alone won’t solve our supply chain issues—we need a comprehensive industrial policy.’ Meanwhile, global partners have reacted cautiously. The European Commission has stated it will ‘monitor the situation closely’ and ‘take all necessary steps to protect EU interests,’ while China’s Ministry of Commerce has called the tariffs ‘a clear violation of WTO rules.’

Historical Precedents: How Section 232 Has Been Used Before

Section 232 is a rarely used but powerful tool in presidential trade authority. Its most famous application was in 2018, when President Trump imposed 25% tariffs on steel imports and 10% on aluminum, citing national security concerns under Section 232. The move sparked global backlash, with the EU, Canada, and Mexico imposing retaliatory tariffs on U.S. goods like bourbon and motorcycles. The steel tariffs remain in place today, despite legal challenges. Before 2018, the last major Section 232 action was in 1982, when President Reagan restricted imports of machine tools to protect the domestic industry. The pharmaceutical tariffs represent the first time Section 232 has been applied to a healthcare product, signaling a new era of ‘health security’ as a justification for trade restrictions.

What’s Next? Timeline and Potential Long-Term Effects

The tariffs will take effect in two phases: July 31, 2026, for companies listed in Annex III of the proclamation, and September 29, 2026, for all others. Over the next four years, the administration will monitor compliance with onshoring plans and MFN pricing agreements, adjusting tariffs as needed. By 2030, the goal is to have a ‘resilient, domestically resilient pharmaceutical manufacturing base’ capable of meeting at least 50% of U.S. demand for critical drugs and APIs. Long-term effects could include a resurgence of U.S.-based API production, higher drug prices for uninsured or underinsured Americans, and potential retaliation from trading partners. The administration has also signaled interest in expanding the program to include generic drugs if import reliance continues to rise.

‘This is not about protectionism—it’s about survival. We cannot allow our national security to depend on foreign supply chains that can be disrupted by a single geopolitical event.’ — Wilbur Ross, Secretary of Commerce, April 2026

Frequently Asked Questions About the Pharmaceutical Tariffs